MEDIROM Healthcare Techs 주식 (NASDAQ: MRM)

에 대한 최신 뉴스 MEDIROM Healthcare Techs (NASDAQ:MRM) 주식

MEDIROM Healthcare Techs

MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

ACCD

화요일 오전 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 펩시코(NASDAQ:PEP)의 분기 이익이 주당 2.29달러, 매출이 238억 3천만 달러로 예상되며, 이 회사는 개장 전에 실적을 발표할 예정ㅇ;다. 월요일에 펩시코의 주식은 0.5% 하락하여 167.21달러로 거래를 마쳤다.

화요일 주목해야 할 주식: 펩시코, 메디롬 헬스케어, 아콜레이드 및 2종목

MEDIROM Healthcare Technologies Inc. - American Depositary Share

MEDIROM Healthcare Technologies Inc

MMA Offshore Ltd

MariMed Inc

MIRAMAR RESOURCES LTD by MIRAMAR RESOURCES LTD

<a href="https://www.benzinga.com/events/cannabis-conference/livestream/" title="https://www.benzinga.com/events/cannabis-conference/livestream/">https://www.benzinga.com/events/cannabis-conference/livestream/</a>

Cannabis

Events

Exclusives

MSOS

Mgo Tax Partner Barbara Webb Says When IRS Catches Up, You Have To Get On An Installment Plan; You Have To Regularly Never Miss A Payment, Stay Current On Current Year's Estimated Taxes, Huge Cash Commitment; They Cannot Afford To Be On An Installment Agreement

KeyBanc analyst John Vinh shared mixed quarterly supply chain findings for the semiconductor sector. The analyst revised several company estimates and price targets.
Though most end markets were weak in analog, he noted indications of auto getting closer to a bottom. Traditional server and AI strength is sustained, with Blackwell on track to launch in the fourth quarter without further delays, as per Vinh.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/10/41211823/whats-going-on-with-super-micro-computer-stock-on-monday" rel="noreferrer noopener">What&#8217;s Going On With Super Micro Computer Stock On Monday?</a>
The analyst&#8217;s feedback on the iPhone 16 launch appears to be better than feared but could be better. Therefore, Vinh downgraded Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) and Synaptics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYNA#NASDAQ">SYNA</a>) to Sector Weight.
Given increased price competition, he expects Qualcomm to lose market share to Mediatek in the mid-to-low-end segment of the smartphone market. This headwind will compound the impacts of Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) ramping up its internal modem.
The Synaptics downgrade reflects its underperformance versus its IoT peers, given limited growth catalysts within its Enterprise &amp; Automotive segment, representing almost 60% of overall revenues and the company&#8217;s highest margins. Vinh flagged increased competition in the Chinese market from local chipmaker HiSilicon as another headwind.
Additionally, the analyst&#8217;s findings were most favorable for Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), mixed for Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), and negative for Monolithic Power Systems, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>), Micron Technology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), Marvell Technology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>), and Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>). He also fine-tuned his estimates on Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>).
Vinh noted that Nvidia&#8217;s Blackwell will likely ramp into mass production beginning in December, contributing over $7 billion in revenues in the fourth quarter. He said Hopper demand remains strong, with fourth-quarter revenues increasing ~15% sequentially.
AMD&#8217;s positive catalysts included traditional server demand, the inflection in Genoa instances in the cloud, demand for MI300X remains on track to ship 500K GPUs in 2024, and a possible update on its next-generation GPU and CPU at its AI event on Thursday.
For Broadcom, Vinh flagged sustained networking demand from improving traditional server demand, share gains from its 800Gb optical DSP launch, and higher revision of CoWoS demand. Broadcom&#8217;s upsides could be offset by Apple preparing its Wi-Fi 7 radio for the iPhone 17 in 2025.
For Micron, Vinh flagged oversupply as Micron prompts Samsung to convert its unused HBM capacity back to traditional DRAM to survive the competition.
Monolithic Power Systems remains vulnerable, given RMAs (Return Merchandise Authorization) for Nvidia H100 AI servers related to field failures associated with Monolithic Power Systems&#8217; power modules increasing again, affecting its market share on Blackwell.
Vinh highlighted his adverse findings from Asia for Marvell Technology. According to the analyst, Marvell is vulnerable to market share loss from the next-generation AWS Trainium 3 loss to Alchip, Google&#8217;s second-generation Axion ARM CPU, and Nvidia&#8217;s development of its 1.6T optical DSP.
Vinh mentioned his negative findings from Asia for Intel. The analyst highlighted Intel&#8217;s server market share loss to AMD and the ramp of Blackwell posing a headwind for Intel. He also flagged the lack of a cost-down AI CPU targeted at mass market AI PCs is likely to result in a share loss for Intel and disappointing feedback on Intel&#8217;s AI chip Gaudi 3.
Photo via Shutterstock
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41227135/next-gen-nvidia-gpus-could-be-revealed-at-ces-2025-what-you-need-to-know" target="_blank" rel="noreferrer noopener">Next-Gen Nvidia GPUs Could Be Revealed at CES 2025 &#8211; What You Need to Know</a></li>
</ul>

Analyst Color

Equities

Analyst Ratings

Tech

AAPL

AVGO

INTC

MPWR

MRVL

NVDA

QCOM

SYNA

Nvidia, AMD Lead The Pack, Broadcom Stable, Intel Falters: Analyst's Latest Take

Barclays analyst Nicholas Campanella maintains Chesapeake Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPK#NYSE">CPK</a>) with a Equal-Weight and raises the price target from $118 to $124.

Price Target

Barclays Maintains Equal-Weight on Chesapeake Utilities, Raises Price Target to $124

Zuanic & Associates Managing Partner Pablo Zuanic Says [if Rescheduling Does Not Happen] They Will Continue To Not Pay Taxes; They Will Do Exactly What They Are Doing Right Now; No Other Big Change; They Don't Have To Pay 280e

Evercore ISI Group analyst Elizabeth Anderson maintains Health Catalyst (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>) with a Outperform and raises the price target from $8 to $10.

HCAT

Evercore ISI Group Maintains Outperform on Health Catalyst, Raises Price Target to $10

Evercore ISI Group analyst Elizabeth Anderson maintains Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) with a In-Line and lowers the price target from $22 to $20.

FTRE

Evercore ISI Group Maintains In-Line on Fortrea Holdings, Lowers Price Target to $20

Barclays analyst Jason Goldberg maintains Capital One Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) with a Equal-Weight and raises the price target from $154 to $158.

Barclays Maintains Equal-Weight on Capital One Finl, Raises Price Target to $158

Lucid has integrated Everspin's MRAM Across Multiple High-Performance EV Models, Strengthening Data Reliability and System Performance
Everspin Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRAM#NASDAQ">MRAM</a>), the world's leading developer and manufacturer of Magnetoresistive Random Access Memory (MRAM) persistent memory solutions, today announced that Lucid Motors will use its PERSYST MRAM in its recently released Gravity SUV. The MR25H256A, a 256Kb serial MRAM, was selected because it meets the AEC Q100 Grade 1 specification of -40C to 125C temperature operation. The MRAM is used in the Gravity to handle data logging and parameter storage to assist in the efficient operation of the all-electric powertrain.

LCID

MRAM

Lucid Motors Selects Everspin Technologies' PERSYST MRAM For Gravity Electric SUV

Macro Economic Events

Economics

Federal Reserve

Fed's Bostic Says Hurricanes Helene And Milton Potentially Have Significant Implications For Economy Over Next Three To Six Months

Barclays analyst Terry Ma maintains Bread Finl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>) with a Underweight and lowers the price target from $37 to $35.

Barclays Maintains Underweight on Bread Finl Hldgs, Lowers Price Target to $35

Blank Rome Co-chair, Cannabis Practice Frank Segall Says Rescheduling Will Not Bring Wells Fargo Into The Industry, Won't Bring Premier Private Equity Firms Into The Federal; They Mandate Legalization

Evercore ISI Group analyst Elizabeth Anderson maintains Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) with a In-Line and raises the price target from $34 to $45.

DOCS

Evercore ISI Group Maintains In-Line on Doximity, Raises Price Target to $45

Zuanic & Associates Managing Partner Pablo Zuanic Says It Is A Very Systematic Process, They Have Not Rushed It; Biggest Issue Is Industry Needs Those Institutional Investors

Evercore ISI Group analyst Elizabeth Anderson maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Outperform and raises the price target from $62 to $75.

Evercore ISI Group Maintains Outperform on CVS Health, Raises Price Target to $75

Evercore ISI Group analyst John Belton maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Outperform and lowers the price target from $270 to $250.

Evercore ISI Group Maintains Outperform on Cencora, Lowers Price Target to $250

Blank Rome Co-chair, Cannabis Practice Frank Segall Says Rescheduling Will Attract New Capital; We All Know Sector Went Up 37% And Now Stocks Are Below Where They Were At The Time; We're Looking At Several Years Away; Dealing With Oversaturation, Lack Of Investor Capital

"We want to be treated like any other industry," Jason Wild, CEO of a leading cannabis operator TerrAscend Corp (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TSNDF#OTCQX">TSNDF</a>) said Tuesday at <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference </a>in Chicago, Illinois. "That&#8217;s all we want. We don&#8217;t want any special treatment. We just want to be not treated like criminals."
The panel, moderated by Tim Seymour, portfolio manager of the Amplify Seymour Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNBS#NYSE">CNBS</a>), discussed the commerce clause, a critical issue for the cannabis industry. The commerce clause in the U.S. Constitution gives the U.S. Congress the power to regulate commerce between states, with foreign nations and Indian tribes.
Emily Paxhia, managing one of the longest-running dedicated cannabis investment funds, Poseidon Investment Management, explained the distinction: intrastate refers to cannabis retail, sales and manufacturing within a single state, while interstate commerce pertains to activities across state lines, involving the dormant commerce clause.
In July, a federal court dismissed a <a href="https://www.benzinga.com/markets/cannabis/24/04/38259298/cannabis-companies-clash-with-justice-dept-over-fed-prohibition-in-major-trial-seek-oral-argumen" target="_blank" rel="noreferrer noopener">lawsuit from major marijuana companies</a> that sought to prevent the U.S. government from enforcing cannabis prohibition against their in-state activities. Judge Mark G. Mastroianni ruled in favor of the <a href="https://www.benzinga.com/markets/cannabis/24/07/39586847/federal-court-dismisses-marijuana-companies-lawsuit-against-government-prohibition">U.S. Department of Justice's motion to dismiss the case.</a>
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41233018/exclusive-ross-gerber-sees-tsunami-of-money-pouring-into-cannabis-companies-upon-federal-legaliz">EXCLUSIVE: Ross Gerber Sees &#8216;Tsunami Of Money&#8217; Pouring Into Cannabis Companies Upon Federal Legalization, Says Cannabis Is One Of &#8216;Biggest&#8217; Opportunities Beyond AI</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h1 class="wp-block-heading">Times Are Changing</h1>
Paxhia highlighted recent developments that signal potential change. "We've all watched as a very dynamic Supreme Court that is sitting today is overturning long-standing rulings and seem to be ruling in favor of states&#8217; rights. <a href="https://www.benzinga.com/government/24/06/39555003/supreme-court-overturns-chevron-ruling-biden-administration-warns-of-convulsive-shock">The Chevron case</a>, being another example that just happened around the interference or the reaching of government into businesses and having an impact on those businesses."
She explained that this is why the cannabis industry doesn't have credit card processing and why insurance providers and banking relationships are limited. She believes the conditions have changed and that the Supreme Court has changed.
<h1 class="wp-block-heading">Silver Bullet</h1>
What is the impact of winning against the dormant commerce clause case?
"If and when we win the case, 280E would go away,&#8221; Wild said. &#8220;That violation of the Controlled Substances Act is what causes cannabis companies to have to pay taxes and not be able to deduct expenses." He suggested winning this case could bring even more benefits to the industry than rescheduling cannabis as it should have a retroactive effect on taxes.
"So the main point of our argument is that our commitment is that state-legal cannabis operators who are following the laws of those specific states should not be considered to be in violation of the Controlled Substances Act," Wild added.
Seymour concluded that while there may be no single solution, this case seems as close to a "silver bullet" as possible. Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39343635/tim-seymour-on-running-a-cannabis-fund-we-focus-on-companies-poised-for-growth">Tim Seymour On Running A Cannabis Fund: &#8216;We Focus On Companies Poised For Growth&#8217;</a></li>
</ul>
Image was created using artificial intelligence.

Government

Legal

Interview

CNBS

TSNDF

Victory In Commerce Clause Case Could Be The Silver Bullet For Cannabis Industry, Experts Say

Global

United States Secretary of Commerce Gina Raimondo Held A Call With China's Commerce Minister On Tuesday

Barclays analyst Ross Sandler maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Overweight and raises the price target from $3900 to $4500.

BKNG

Barclays Maintains Overweight on Booking Holdings, Raises Price Target to $4500

Zuanic & Associates Managing Partner Pablo Zuanic Says Despite Positive Momentum And Fact We Have A Hearing Coming Up And Possibility Very Likely We Will Get Rescheduling We're Still At Seven; We're Not Seeing Consolidation Right Now Is It Goes Valuations Are So Depressed

Medirom Healthcare Technologies, Inc. (MRM) has released an update. Medirom Healthcare Technologies Inc. reported a marginal decrease in total cust...

Medirom Reports Growth in Customer Value Metrics

MEDIROM Healthcare Technologies (MRM) has released an update. MEDIROM Healthcare Technologies Inc., a holistic healthcare provider, has reported a ...

MEDIROM Reports May KPIs and User Growth

Medirom to buy majority stake in Japan Gene Medicine

MEDIROM Healthcare Technologies (MRM) has released an update. MEDIROM Healthcare Technologies Inc. is set to acquire a 70% stake in Japan Gene Medi...

MEDIROM Expands with Genetic Testing Firm Buyout

MEDIROM Healthcare Technologies (MRM) has released an update. MEDIROM Healthcare Technologies Inc. has reported an increase in total customers serv...

MEDIROM Reports Growth and Expanding User Base

MEDIROM Healthcare Technologies (MRM) has released an update. MEDIROM Healthcare Technologies Inc. has announced a capital and business alliance wi...

MEDIROM Forms Alliance with NFES, Boosts Series A Funding

Medirom Mother Labs and NFES Technologies form capital and business alliance

MEDIROM Healthcare Technologies (MRM) has released an update. MEDIROM Healthcare Technologies Inc. has disclosed its July 2024 performance, noting ...

MEDIROM Reports Key July 2024 Performance Metrics

MEDIROM Healthcare Technologies (MRM) has released an update. MEDIROM Healthcare Technologies Inc. reports a slight decrease in total customers ser...

MEDIROM Reports Mixed August 2024 KPIs, Health App Grows

Medirom Healthcare plans to acquire the majority of Japan Gene Medicine

Press Releases

SYLA Technologies to Participate in the NASDAQ JAPAN IR EVENT

UPDATED - SYLA Technologies to Participate in the NASDAQ JAPAN IR EVENT

Lead Real Estate Co., Ltd. to Participate in Nasdaq Japan IR Event on June 20, 2024

"NASDAQ JAPAN IR EVENT" to Be Held at Nasdaq MarketSite on June 20, 2024

MEDIROM Healthcare Technologies Inc. Announces Financial Results for Fiscal Year 2023

The first JAPAN IR Event 2024 was held at Nasdaq's U.S. headquarters

MEDIROM Healthcare Technologies Announces Acquisition of Japan Gene Medicine Corporation

Health Care

MEDIROM Healthcare Technologies Announces Business Transfer from Y's, Inc.

Capital and Business Alliance Formed Between MEDIROM MOTHER Labs and NFES Technologies

MEDIROM Rehab Solutions Inc. Acquires Rehabilitation Centers from Y's, Inc.

ELWS

Allurion Technologies

The Beachbody Company, Inc. Class A Common Stock

Beachbody Co

Carriage Servs

E-Home Household Service Holdings Limited - Ordinary shares

E-Home Household Service

European Wax Center, Inc. - Class A Common Stock

European Wax Center

Frontdoor

H&R Block

Junee

Mister Car Wash

Alta Global Group Limited Ordinary Shares

Alta Global Group

OneSpaWorld Holdings Limited - Common Shares

OneSpaWorld Holdings

Wag Group

Regis

Service Corporation International Common Stock

Service Corp Intl

SunCar Technology Group Inc. - Ordinary Shares

SunCar Tech Gr

WW International

XWELL

화요일 오전 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:
1. 펩시코(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>)의 분기 이익이 주당 2.29달러, 매출이 238억 3천만 달러로 예상되며, 이 회사는 개장 전에 실적을 발표할 예정ㅇ;다. 월요일에 펩시코의 주식은 0.5% 하락하여 167.21달러로 거래를 마쳤다.
2. 메디롬 헬스케어 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>)는 Y&#8217;s, Inc.의 모든 재활 센터를 인수했다고 발표했다. 그러나 거래 조건은 공개되지 않았다. 메디롬 헬스케어의 주식은 시간외 거래에서 7.2% 상승하여 2.84달러로 거래되었다.
3. 애널리스트들은 아콜레이드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>)가 주당 44센트의 분기 손실을 기록하고 매출이 1억 5백만 달러에 이를 것으로 예상하고 있으며, 이 회사는 시장 개장 전에 실적을 발표할 예정이다. 아콜레이드의 주식은 시간외 거래에서 3% 상승하여 4.0899달러로 거래되었다.
프리마켓 보도를 <a href="https://www.benzinga.com/premarket/">여기서</a> 확인하세요.
4. 벤치마크 일렉트로닉스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHE#NYSE">BHE</a>)는 브라이언 슈마커(Bryan Schumaker)를 CFO로 임명했다고 발표했다. 브라이언 벤치마크의 주식은 시간외 거래에서 0.1% 하락하여 43.69달러로 거래되었다.
5. 애널리스트들은 사라토가 인베스트먼트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAR#NYSE">SAR</a>)가 주당 94센트의 분기 이익과 3,712만 달러의 매출을 기록할 것으로 예상하고 있으며, 시장 마감 후 실적을 발표할 예정이다. 사라토가 인베스트먼트의 주식은 시간외 거래에서 0.8% 상승하여 23.45달러로 거래되었다.
이것도 확인해보세요:
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41213879/top-3-financials-stocks-that-may-jump-this-quarter">이번 분기에 급등할 수 있는 상위 3개 금융주</a></li>
</ul>
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

MEDIROM Healthcare Techs

뉴스

에 대한 최신 뉴스 MEDIROM Healthcare Techs (NASDAQ:MRM) 주식

화요일, 10월 08, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌